Chester County News and Community Website
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that interim Phase 2 trial data for its investigational therapy istaroxime will be presented at the Heart Failure Society of America’s …
Windtree Therapeutics Reports Promising Interim Results for Heart Failure Drug Candidate Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has reported encouraging interim results from its ongoing SEISMiC C Phase 2 trial evaluating istaroxime in patients with SCAI Stage C cardiogenic shock, …
Windtree Advances Istaroxime Toward Global Phase 3 Following Positive Interim Study Results Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced major reductions in its outstanding Series C and Series D preferred shares, positioning the company to limit future equity dilution as it …
Windtree Therapeutics Cuts Preferred Stock by Over 99% Ahead of Crypto Strategy Rollout Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced two major equity financing agreements totaling up to $520 million, positioning the company to significantly expand its holdings of BNB cryptocurrency, …
Windtree Therapeutics Secures $520 Million in Equity Agreements to Expand BNB Cryptocurrency Holdings Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has entered into a strategic partnership with Kraken, a leading global cryptocurrency platform, to support custody, trading, and over-the-counter (OTC) services for …
Windtree Taps Kraken to Power BNB Crypto Treasury Strategy Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced a transformative financing agreement this week, unveiling plans to raise up to $200 million to launch a first-of-its-kind BNB crypto treasury …
Windtree Therapeutics to Launch BNB Crypto Treasury Strategy in Groundbreaking $200 Million Deal Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that the U.S. Patent and Trademark Office has issued a new patent covering its lead investigational therapy, istaroxime, for intravenous treatment …
Windtree Therapeutics Secures U.S. Patent for Istaroxime Heart Failure Treatment Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has achieved a major milestone in its Phase 2 SEISMiC C study, announcing the planned enrollment of 20 patients for its interim …
Windtree Therapeutics Advances Istaroxime Phase 2 Study with Interim Analysis Enrollment Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the publication of findings from its Phase 2 SEISMiC B study on istaroxime in the Journal of Heart and Lung …
Windtree Therapeutics Announces Promising Phase 2 Study Results for Istaroxime Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT), announced that it has received a non-binding letter of intent to sell its preclinical oncology aPKCi inhibitor platform for $7 million in …
Windtree Therapeutics Receives $7 Million Offer for Preclinical Oncology Platform Read More